Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by PepGen Inc. PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights August 08, 2024 From PepGen Inc. Via Business Wire Tickers PEPG PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy July 30, 2024 From PepGen Inc. Via Business Wire Tickers PEPG PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications July 02, 2024 From PepGen Inc. Via Business Wire Tickers PEPG PepGen Announces Executive Team Promotions June 11, 2024 From PepGen Inc. Via Business Wire Tickers PEPG PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights May 14, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen to Participate in Upcoming Investor Conferences March 13, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy March 13, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments March 06, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy March 04, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 February 20, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock February 07, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG Mary Beth DeLena Joins PepGen as General Counsel and Secretary January 17, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping January 08, 2024 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) December 18, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors November 15, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments November 08, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) October 12, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology September 27, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 September 06, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences September 06, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference September 01, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments August 08, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 June 13, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) May 30, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy May 18, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments May 11, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call March 16, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference March 13, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen to Participate in the SVB Securities Global Biopharma Conference February 09, 2023 From PepGen Inc. Via GlobeNewswire Tickers PEPG PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies December 07, 2022 From PepGen Inc. Via GlobeNewswire Tickers PEPG Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.